Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-1020 in Major Depressive Disorder
NCT06309277Phase 2Completed
- Sponsor
- Gilgamesh Pharmaceuticals
- Start
- Feb 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of blixeprodil in major depressive disorder (MDD), sponsored by Gilgamesh Pharmaceuticals. Started Feb 2024; status: completed.
02
Drugs
blixeprodil
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06309277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06309277.